Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

Longzhen Cui, Yan Liu, Yifan Pang, Tingting Qian, Liang Quan, Zhiheng Cheng, Yifeng Dai, Xu Ye, Ying Pang, Jinlong Shi, Xiaoyan Ke, Depei Wu, Lin Fu*

*Corresponding author voor dit werk

    Onderzoeksoutputpeer review

    10 Citaten (Scopus)
    101 Downloads (Pure)

    Samenvatting

    Relapsed and refractory acute myeloid leukemia (R/R AML) has complicated pathogenesis. Its treatment is complicated, and the prognosis is poor. So far, there is no consensus on what is the optimal treatment strategy. With the deepening of research, new chemotherapy regimens, new small molecule inhibitors, and immunotherapy have been increasingly applied to clinical trials, providing more possibilities for the treatment of R/R AML. The most effective treatment for patients who achieve complete remission after recurrence is still sequential conditioning therapy followed by allogeneic hematopoietic cell transplantation. Finding the best combination of treatments is still an important goal for the future.

    Originele taal-2English
    Pagina's (van-tot)1-14
    Aantal pagina's14
    TijdschriftCancer Gene Therapy
    Volume27
    Nummer van het tijdschrift1-2
    DOI's
    StatusPublished - feb.-2020

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit